Deutsche Bank
CLDI icon

Deutsche Bank’s Calidi Biotherapeutics CLDI Stock Holding History

Deutsche Bank’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-73
Closed -$1.46M – 3726
2023
Q2 		$1.46M Hold
73
– – ﹤0.01% 1775
2023
Q1 		$1.43M Buy
+73
New +$1.43M ﹤0.01% 1879
2022
Q3 		– Sell
-52
Closed -$994K – 3985
2022
Q2 		$994K Hold
52
– – ﹤0.01% 2189
2022
Q1 		$989K Hold
52
– – ﹤0.01% 2352
2021
Q4 		$981K Buy
+52
New +$981K ﹤0.01% 2450

Other funds holding CLDI

MC
Meteora Capital Boca Raton, Florida $1.21B AUM 13.69% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $2.8B AUM 13.35% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
SAMC
Spectrum Asset Management (California) Newport Beach, California $360M AUM 19.03% 1-Year Est. Return
RWI
Red Wave Investments Dillsburg, Pennsylvania $394M AUM 20.27% 1-Year Est. Return
DIM
Delta Investment Management San Francisco, California $608M AUM 25.3% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Deutsche Bank's CLDI Position: Q3 2023 in Review

Deutsche Bank sold out of Calidi Biotherapeutics (CLDI) in Q3 2023, closing a stake of 73 shares — an estimated $1.46M sold.

Deutsche Bank first reported a position in CLDI in Q4 2021 and held it in 5 quarters. The position peaked at $1.46M in Q2 2023. 10 funds tracked by Wall St. Rank hold CLDI as of Q3 2023.

  • Deutsche Bank reported no remaining Calidi Biotherapeutics position as of Q3 2023 after selling out during the quarter.
  • Deutsche Bank sold 73 Calidi Biotherapeutics shares in Q3 2023, an estimated $1.46M.
  • Deutsche Bank first reported a position in Calidi Biotherapeutics in Q4 2021 and held it in 5 quarters.
  • Deutsche Bank's Calidi Biotherapeutics position peaked at $1.46M in Q2 2023.
  • 10 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2023.

Based on Deutsche Bank's 13F filing for Q3 2023, filed 9 Nov 2023.